CD276

Cluster of Differentiation 276 (CD276) or B7 Homolog 3 (B7-H3) is a human protein encoded by the CD276 gene.[4]

CD276
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCD276, 4Ig-B7-H3, B7-H3, B7H3, B7RP-2, CD276 molecule
External IDsOMIM: 605715 MGI: 2183926 HomoloGene: 11892 GeneCards: CD276
Gene location (Human)
Chr.Chromosome 15 (human)[1]
Band15q24.1Start73,683,966 bp[1]
End73,714,514 bp[1]
Orthologs
SpeciesHumanMouse
Entrez

80381

102657

Ensembl

ENSG00000103855

ENSMUSG00000035914

UniProt

Q5ZPR3

Q8VE98

RefSeq (mRNA)

NM_001024736
NM_025240
NM_001329628
NM_001329629

NM_133983

RefSeq (protein)

NP_001019907
NP_001316557
NP_001316558
NP_079516

NP_598744

Location (UCSC)Chr 15: 73.68 – 73.71 Mbn/a
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

Structure

B7-H3 is a 316 amino acid-long type I transmembrane protein, existing in two isoforms determined by its extracellular domain. In mice, the extracellular domain consists of a single pair of immunoglobulin variable (IgV)-like and immunoglobulin constant (IgC)-like domains, whereas in humans it consists of one pair (2Ig-B7-H3) or two identical pairs (4Ig-B7-H3) due to exon duplication. B7-H3 mRNA is expressed in most normal tissues. In contrast, B7-H3 protein has a very limited expression on normal tissues because of its post-transcriptional regulation by microRNAs. However, B7-H3 protein is expressed at high frequency on many different cancer types (60% of all cancers). [5]

Function

In non-malignant tissues, B7-H3 has a predominantly inhibitory role in adaptive immunity, suppressing T cell activation and proliferation. In malignant tissues, B7-H3 is an immune checkpoint molecule that inhibits tumor antigen-specific immune responses. B7-H3 also possesses non-immunological pro-tumorigenic functions such as promoting migration, invasion, angiogenesis, chemoresistance, epithelial-to-mesenchymal transition, and affecting tumor cell metabolism.[5]

Due to its selective expression on solid tumors, B7-H3 has been the target of several anticancer agents such as enoblituzumab (MGA271),[6] omburtamab, MGD009, MGC018, DS-7300a, and CAR T cells.[5]

See also

References

  1. GRCh38: Ensembl release 89: ENSG00000103855 - Ensembl, May 2017
  2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Entrez Gene: CD276 CD276 molecule".
  5. Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S (October 2020). "B7-H3: an attractive target for antibody-based immunotherapy". Clinical Cancer Research: clincanres.2584.2020. doi:10.1158/1078-0432.CCR-20-2584. PMID 33051306.
  6. "Servier Pays MacroGenics $20M for Option to Anticancer Antibody - GEN". GEN.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.